Clinical Trial Update: Safety and Efficacy of ULSC on Disease Severity and Steroid Tapering in Participants With Dermatomyositis/ Polymyositis (DM/PM), Also Known as Idiopathic Inflammatory Myopathy (IIM) [Phase 2, Phase 3]

View source ↗

Summary

The sponsor reports an ongoing Phase 2/3 trial assessing the safety and efficacy of ULSC in reducing disease severity and aiding steroid tapering in dermatomyos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dermatomyositis
• Idiopathic Inflammatory Myopathy
• Polymyositis

Drugs mentioned

• ULSC

Snippet

Sponsor: Restem, LLC. | Conditions: Idiopathic Inflammatory Myositis (IIM), DERMATOMYOSITIS OR POLYMYOSITIS | Phase 2, Phase 3 | Status: RECRUITING